Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers.
Relapsed germ cell cancer
high dose chemotherapy
stem cell transplant
survival
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
26
08
2020
revised:
03
09
2020
accepted:
15
09
2020
entrez:
4
11
2020
pubmed:
5
11
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
High-dose chemotherapy (HDCT) and stem cell transplantation (SCT) have been established as the standard of care in patients with relapsed germ cell tumours (GCTs). We evaluated the safety, efficacy and tolerability of HDCT/ SCT in patients with relapsed GCTs. Twenty-eight patients with relapsed GCTs, treated with HDCT, were included in this study. The conditioning regime was carboplatin, etoposide, cyclophosphamide and paclitaxel. Clinical, radiological imaging and tumour markers determined treatment outcomes. Median age was 35 years (range=21-57 years) with 26 males and 2 females. Median time to first relapse was 6 months. Median time to progression after 2 In relapsed GCT patients, median survival may exceed 5 years post-HDCT and SCT.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
High-dose chemotherapy (HDCT) and stem cell transplantation (SCT) have been established as the standard of care in patients with relapsed germ cell tumours (GCTs). We evaluated the safety, efficacy and tolerability of HDCT/ SCT in patients with relapsed GCTs.
PATIENTS AND METHODS
METHODS
Twenty-eight patients with relapsed GCTs, treated with HDCT, were included in this study. The conditioning regime was carboplatin, etoposide, cyclophosphamide and paclitaxel. Clinical, radiological imaging and tumour markers determined treatment outcomes.
RESULTS
RESULTS
Median age was 35 years (range=21-57 years) with 26 males and 2 females. Median time to first relapse was 6 months. Median time to progression after 2
CONCLUSION
CONCLUSIONS
In relapsed GCT patients, median survival may exceed 5 years post-HDCT and SCT.
Identifiants
pubmed: 33144484
pii: 34/6/3675
doi: 10.21873/invivo.12215
pmc: PMC7811657
doi:
Substances chimiques
Carboplatin
BG3F62OND5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3675-3679Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
J Clin Oncol. 1996 Oct;14(10):2638-45
pubmed: 8874322
N Engl J Med. 2007 Jul 26;357(4):340-8
pubmed: 17652649
Urol Oncol. 2011 May-Jun;29(3):284-90
pubmed: 19556152
Adv Urol. 2018 Mar 15;2018:7272541
pubmed: 29736168
J Clin Oncol. 1998 Feb;16(2):702-6
pubmed: 9469360
Urol Clin North Am. 2019 Aug;46(3):439-448
pubmed: 31277738
World J Stem Cells. 2015 Dec 26;7(11):1222-32
pubmed: 26730267
J Clin Oncol. 2003 Nov 15;21(22):4083-91
pubmed: 14568987
Anticancer Res. 2019 Sep;39(9):4911-4916
pubmed: 31519595
J Clin Oncol. 2017 Apr 1;35(10):1036-1040
pubmed: 27992270
J Clin Oncol. 2012 Mar 10;30(8):800-5
pubmed: 22291076
J Clin Oncol. 1997 Jul;15(7):2559-63
pubmed: 9215825
Ann Oncol. 2005 Jul;16(7):1152-9
pubmed: 15928070
J Cancer. 2011;2:374-7
pubmed: 21750688
Intern Med J. 2014 Aug;44(8):771-8
pubmed: 24893627